Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035338 | 0.86 | CYP2A6 (1.00) | CYP2A6CYP2B6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8182704 | 0.82 | CYP2A6 (0.67) | CYP2A6CYP2B6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8182699 | 0.79 | CYP2A6 (0.62) | CYP2A6CYP2B6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14392676 | 0.78 | CYP2A6 (0.61) | CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL3615252 | 0.77 | CYP2A6 (1.00) | CYP2A6CYP2B6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30963844 | 0.77 | CYP2A6 (0.74) | CYP2A6CYP2B6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30714232 | 0.77 | — | — | |
| Methane SCHEMBL7424052 | 0.76 | CYP2A6 (0.71) | CYP2A6CYP2B6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5115735 | 0.75 | CYP2A6 (0.60) | CYP2A6PDGFRBPDGFRACYP11B1CYP11B2 | |
| SCHEMBL7508962 | 0.75 | CYP2A6 (0.70) | CYP2A6CYP2B6CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-8609708-B2 | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-12-17 | — | — | US | disclosed |
| US-6852721-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| CN-1436191-A | Heteroaryl diazabicycloalkanes as nicotinic cholinergic receptor ligands | TARGACEPT INC (US) | 2003-08-13 | — | — | CN | disclosed |
| WO-2001090109-A9 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT INC (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-1289996-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | Targacept, Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1147107-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001090109-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| EP-1147107-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6265403-B1 | TYROSINE INHIBITORS | MERCK & CO., INC. | 2001-07-24 | — | — | US | disclosed |
| WO-2000043393-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | CYP2D6, CYP3A5, CYP2B6 | CYP2A6 12/4885CYP2B6 3/4885CYP3A4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.